SCHEMBL6493547

SCHEMBL6493547

Cc1ccc(C2=C(C(=O)Nc3ccc(NCCc4ccccn4)cc3)CCCCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.45
HTT P42858 2/20 0.45
CTNNB1 P35222 2/20 0.44
TCF7L2 Q9NQB0 2/20 0.44
RAB9A P51151 7/20 0.44
NPC1 O15118 6/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
KDR P35968 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
CNR1 P21554 1/20 0.41
MAPT P10636 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
DHODH Q02127 1/20 0.41
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490871 1.00 L3MBTL1 (0.45) L3MBTL1HTTCTNNB1TCF7L2RAB9A
SCHEMBL6490864 1.00 L3MBTL1 (0.45) L3MBTL1HTTCTNNB1TCF7L2RAB9A
SCHEMBL6489289 0.99 L3MBTL1 (0.46) L3MBTL1HTTCTNNB1TCF7L2RAB9A
SCHEMBL6487298 0.97 L3MBTL1 (0.46) L3MBTL1HTTCTNNB1TCF7L2RAB9A
SCHEMBL6491912 0.90 RAB9A (0.48) HTTCTNNB1TCF7L2RAB9ANPC1
SCHEMBL6503827 0.90 HTT (0.50) L3MBTL1HTTCTNNB1TCF7L2RAB9A
SCHEMBL6501992 0.89 CNR1 (0.54) CTNNB1TCF7L2RAB9ANPC1SMN1; SMN2
SCHEMBL6491345 0.89 CYP1A2 (0.44) L3MBTL1HTTCTNNB1TCF7L2RAB9A
SCHEMBL6487840 0.89 TRPV1 (0.48)
SCHEMBL6500678 0.89 TRPV1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 L3MBTL1 2276/4885HTT 2574/4885CTNNB1 1793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.